» Articles » PMID: 36765626

IL-15 Prevents the Development of T-ALL from Aberrant Thymocytes with Impaired DNA Repair Functions and Increased NOTCH1 Activation

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Feb 11
PMID 36765626
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported that NOD. mice lacking interleukin-15 (IL-15), or IL-15 receptor alpha-chain, develop T-acute lymphoblastic leukemia (T-ALL). To understand the mechanisms by which IL-15 signaling controls T-ALL development, we studied the thymocyte developmental events in IL-15-deficient mice from NOD and C57BL/6 genetic backgrounds. Both kinds of mice develop T-ALL characterized by circulating TCR-negative cells expressing CD4, CD8 or both. Analyses of thymocytes in NOD. mice prior to T-ALL development revealed discernible changes within the CD4CD8 double-negative (DN) thymocyte developmental stages and increased frequencies of CD4CD8 double-positive cells with a high proportion of TCR-negative CD4 and CD8 cells. The DN cells also showed elevated expressions of CXCR4 and CD117, molecules implicated in the expansion of DN thymocytes. T-ALL cell lines and primary leukemic cells from IL-15-deficient NOD. and C57BL/6. mice displayed increased NOTCH1 activation that was inhibited by NOTCH1 inhibitors and blockers of the PI3K/AKT pathway. Primary leukemic cells from NOD. mice survived and expanded when cultured with MS5 thymic stromal cells expressing Delta-like ligand 4 and supplemented with IL-7 and FLT3 ligand. These findings suggest that IL-15 signaling in the thymus controls T-ALL development from aberrant thymocytes with an impaired DNA repair capacity and increased NOTCH1 activation.

Citing Articles

Research progress of interleukin-15 in cancer immunotherapy.

Cai M, Huang X, Huang X, Ju D, Zhu Y, Ye L Front Pharmacol. 2023; 14:1184703.

PMID: 37251333 PMC: 10213988. DOI: 10.3389/fphar.2023.1184703.


An Update on Clinical Trials and Potential Therapeutic Strategies in T-Cell Acute Lymphoblastic Leukemia.

Patel J, Gao X, Wang H Int J Mol Sci. 2023; 24(8).

PMID: 37108359 PMC: 10139433. DOI: 10.3390/ijms24087201.

References
1.
Alpdogan O, Eng J, Muriglan S, Willis L, Hubbard V, Tjoe K . Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood. 2004; 105(2):865-73. DOI: 10.1182/blood-2003-09-3344. View

2.
Chadwick N, Zeef L, Portillo V, Fennessy C, Warrander F, Hoyle S . Identification of novel Notch target genes in T cell leukaemia. Mol Cancer. 2009; 8:35. PMC: 2698846. DOI: 10.1186/1476-4598-8-35. View

3.
Sanda T, Leong W . TAL1 as a master oncogenic transcription factor in T-cell acute lymphoblastic leukemia. Exp Hematol. 2017; 53:7-15. DOI: 10.1016/j.exphem.2017.06.001. View

4.
Aly R, Taalab M, Ghazy H . Influence of interleukin-15 polymorphism on the survival of adult patients with acute lymphoblastic leukemia in Egypt. Leuk Lymphoma. 2014; 56(1):151-6. DOI: 10.3109/10428194.2014.910659. View

5.
Shah D, Zuniga-Pflucker J . An overview of the intrathymic intricacies of T cell development. J Immunol. 2014; 192(9):4017-23. DOI: 10.4049/jimmunol.1302259. View